KR20130132892A - 용리제 용액 - Google Patents

용리제 용액 Download PDF

Info

Publication number
KR20130132892A
KR20130132892A KR1020137017012A KR20137017012A KR20130132892A KR 20130132892 A KR20130132892 A KR 20130132892A KR 1020137017012 A KR1020137017012 A KR 1020137017012A KR 20137017012 A KR20137017012 A KR 20137017012A KR 20130132892 A KR20130132892 A KR 20130132892A
Authority
KR
South Korea
Prior art keywords
eluent
reaction
solution
labeled
exchange column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137017012A
Other languages
English (en)
Korean (ko)
Inventor
토릴드 윅스트롬
앤더스 스베드버그
오엘 크리스티안 헬스투엔
대그 엠. 에브제
리엔 오첸펠드
Original Assignee
지이 헬쓰케어 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지이 헬쓰케어 리미티드 filed Critical 지이 헬쓰케어 리미티드
Publication of KR20130132892A publication Critical patent/KR20130132892A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B9/00—General methods of preparing halides
    • C01B9/08—Fluorides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137017012A 2010-12-29 2011-12-21 용리제 용액 Ceased KR20130132892A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061427839P 2010-12-29 2010-12-29
US61/427,839 2010-12-29
PCT/EP2011/073670 WO2012089594A1 (en) 2010-12-29 2011-12-21 Eluent solution

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197001271A Division KR102218263B1 (ko) 2010-12-29 2011-12-21 용리제 용액

Publications (1)

Publication Number Publication Date
KR20130132892A true KR20130132892A (ko) 2013-12-05

Family

ID=45495902

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020137017012A Ceased KR20130132892A (ko) 2010-12-29 2011-12-21 용리제 용액
KR1020197001271A Active KR102218263B1 (ko) 2010-12-29 2011-12-21 용리제 용액
KR1020197030135A Active KR102137348B1 (ko) 2010-12-29 2012-12-21 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197001271A Active KR102218263B1 (ko) 2010-12-29 2011-12-21 용리제 용액
KR1020197030135A Active KR102137348B1 (ko) 2010-12-29 2012-12-21 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물

Country Status (16)

Country Link
US (3) US11504430B2 (enExample)
EP (2) EP2658831B1 (enExample)
JP (1) JP6018581B2 (enExample)
KR (3) KR20130132892A (enExample)
CN (2) CN103270004A (enExample)
AU (1) AU2011351550B2 (enExample)
BR (2) BR112013015396B1 (enExample)
CA (1) CA2823063C (enExample)
DK (3) DK2658831T3 (enExample)
ES (2) ES2621950T3 (enExample)
MX (1) MX363538B (enExample)
PL (2) PL2658831T3 (enExample)
PT (2) PT2793954T (enExample)
RU (1) RU2608932C2 (enExample)
SG (1) SG10201805198TA (enExample)
WO (1) WO2012089594A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180016418A (ko) * 2015-05-20 2018-02-14 아웃앤아웃 케미스트리 에스피알엘 방사성의약품의 제조를 위한 복수의 합성 공정들의 연속 수행 방법, 및 상기 방법을 수행하기 위한 장치 및 카세트

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130132892A (ko) * 2010-12-29 2013-12-05 지이 헬쓰케어 리미티드 용리제 용액
CA2852840A1 (en) * 2011-10-19 2013-04-25 Piramal Imaging Sa Improved method for production of f-18 labeled a.beta. ligands
JP6446268B2 (ja) * 2011-12-21 2018-12-26 ジーイー・ヘルスケア・リミテッド クエン酸緩衝液中の１８ｆ−フルシクロビン組成物
GB201411569D0 (en) 2014-06-30 2014-08-13 Ge Healthcare Ltd Novel formulation and method of synthesis
US11534494B2 (en) 2011-12-21 2022-12-27 Ge Healthcare Limited Formulation and method of synthesis
GB201214220D0 (en) * 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis
GB201221266D0 (en) 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201305687D0 (en) * 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
ES3005832T3 (en) 2013-11-13 2025-03-17 Ge Healthcare Ltd Dual run cassette for the synthesis of 18f-labelled compounds
WO2015143019A2 (en) * 2014-03-18 2015-09-24 Mayo Foundation For Medical Education And Research Gaseous f-18 technologies
JP6827709B2 (ja) * 2016-04-25 2021-02-10 日本メジフィジックス株式会社 ２−［１８ｆ］フルオロ−２−デオキシ−ｄ−グルコースの製造方法
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
JP7148121B2 (ja) * 2018-08-31 2022-10-05 国立大学法人北海道大学 放射性核種１８ｆの精製方法
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
US20230390426A1 (en) * 2020-10-22 2023-12-07 Nihon Medi-Physics Co., Ltd. Method for producing radioactive zirconium complex
JP7127164B2 (ja) * 2021-01-19 2022-08-29 日本メジフィジックス株式会社 ２－［１８ｆ］フルオロ－２－デオキシ－ｄ－グルコースの製造方法
CN113372399A (zh) * 2021-06-04 2021-09-10 江苏华益科技有限公司 一种氟[18f]脱氧葡糖注射液的合成方法
CN119591463B (zh) * 2024-11-27 2025-12-09 遵义医科大学 一种 [18f] 三氟甲基末端烯烃的放射性标记方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5425063A (en) * 1993-04-05 1995-06-13 Associated Universities, Inc. Method for selective recovery of PET-usable quantities of [18 F] fluoride and [13 N] nitrate/nitrite from a single irradiation of low-enriched [18 O] water
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
RU2165266C1 (ru) * 2000-06-28 2001-04-20 Центральный научно-исследовательский рентгенорадиологический институт Способ получения [2-18f]-2-дезоксиглюкозы
EP1356827A1 (en) 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
BR0215913A (pt) 2002-11-05 2005-08-09 Ion Beam Applic Sa Composição de radiofármacos rotulados com 18-f e processo para obtê-los
GB0422004D0 (en) * 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
GB0425501D0 (en) * 2004-11-19 2004-12-22 Amersham Plc Fluoridation process
US7235216B2 (en) * 2005-05-01 2007-06-26 Iba Molecular North America, Inc. Apparatus and method for producing radiopharmaceuticals
GB0524851D0 (en) * 2005-12-06 2006-01-11 Ge Healthcare Ltd Radiolabelling method using polymers
WO2007148088A2 (en) * 2006-06-21 2007-12-27 Ge Healthcare Limited Radiopharmaceutical products
US20100056826A1 (en) 2006-11-09 2010-03-04 Nihon Medi-Physicis Co., Ltd. Radioactive diagnostic imaging agent
US8790620B2 (en) 2006-12-21 2014-07-29 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
EP2119458B9 (en) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Method for production of radiation diagnostic imaging agent
EP2017359A3 (en) * 2007-06-11 2009-08-05 Trasis S.A. Method for the elution of 18F fluoride trapped on an anion-exchange resin in a form suitable for efficient radiolabeling without any evaporation step
KR101009712B1 (ko) 2007-02-22 2011-01-19 재단법인 아산사회복지재단 양성자성 용매와 이에 녹는 염들을 이용한 음이온 교환고분자 지지체로부터의 플루오린-18 플루오라이드 용리와이를 이용한 플루오린-18의 표지방법
US20100150835A1 (en) * 2007-02-27 2010-06-17 Bengt Langstrom Synthesis of [18F] Fluoromethyl Benzene Using Benzyl Pentafluorobenzenesulfonate
EP1990310A1 (en) * 2007-04-23 2008-11-12 Trasis S.A. Method for the preparation of reactive 18F fluoride, and for the labeling of radiotracers, using a modified non-ionic solid support and without any evaporation step
WO2009045535A2 (en) * 2007-10-04 2009-04-09 Sloan-Kettering Institute For Cancer Research Fluorine-18 derivative of dasatinib and uses thereof
US8269035B2 (en) 2007-12-19 2012-09-18 Nihon Medi-Physics Co., Ltd. Process for production of radioactive-fluorine-labeled organic compound
US20090171272A1 (en) 2007-12-29 2009-07-02 Tegg Troy T Deflectable sheath and catheter assembly
EP2238074A2 (en) * 2008-01-03 2010-10-13 GE Healthcare UK Limited Fluoride processing method
EP2110367A1 (en) * 2008-04-14 2009-10-21 Bayer Schering Pharma Aktiengesellschaft Purification strategy for direct nucleophilic procedures
GB0819293D0 (en) * 2008-10-21 2008-11-26 Hammersmith Imanet Ltd Radiofluorination
CN102239130A (zh) * 2008-12-04 2011-11-09 拜耳先灵医药股份有限公司 放射性同位素标记的赖氨酸和鸟氨酸衍生物、它们的用途和制备方法
TW201033713A (en) 2009-03-03 2010-09-16 Wintek Corp Reflective color-changing liquid crystal display
CA2801530C (en) * 2010-06-04 2017-09-12 Piramal Imaging Sa Method for production of f-18 labeled amyloid beta ligands
KR20130132892A (ko) * 2010-12-29 2013-12-05 지이 헬쓰케어 리미티드 용리제 용액
GB201214220D0 (en) * 2012-08-09 2012-09-19 Ge Healthcare Ltd Radiosynthesis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180016418A (ko) * 2015-05-20 2018-02-14 아웃앤아웃 케미스트리 에스피알엘 방사성의약품의 제조를 위한 복수의 합성 공정들의 연속 수행 방법, 및 상기 방법을 수행하기 위한 장치 및 카세트
US11820790B2 (en) 2015-05-20 2023-11-21 Out And Out Chemistry S.P.R.L. Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series
US12583881B2 (en) 2015-05-20 2026-03-24 Out And Out Chemistry S.P.R.L. Device and cassette for performing a plurality of synthesis processes of preparing a radiopharmaceutical in series

Also Published As

Publication number Publication date
US20190192660A1 (en) 2019-06-27
ES2621950T3 (es) 2017-07-05
EP2658831B1 (en) 2017-02-15
PL3766522T3 (pl) 2022-07-04
DK3766522T3 (da) 2022-06-13
WO2012089594A1 (en) 2012-07-05
EP3766522B1 (en) 2022-03-23
CA2823063A1 (en) 2012-07-05
CA2823063C (en) 2020-08-11
MX2013007699A (es) 2013-08-15
BR112014015042A2 (pt) 2017-06-13
US20230068052A1 (en) 2023-03-02
JP6018581B2 (ja) 2016-11-02
ES2917875T3 (es) 2022-07-12
BR112014015042B1 (pt) 2021-10-26
DK2658831T3 (en) 2017-04-24
BR112013015396A2 (pt) 2016-09-20
SG10201805198TA (en) 2018-07-30
PL2658831T3 (pl) 2017-07-31
PT2793954T (pt) 2021-01-06
JP2014508731A (ja) 2014-04-10
BR112013015396B1 (pt) 2021-11-03
KR102218263B1 (ko) 2021-02-22
KR20190008994A (ko) 2019-01-25
RU2013126979A (ru) 2015-03-20
KR102137348B1 (ko) 2020-07-23
US11504430B2 (en) 2022-11-22
EP3766522A1 (en) 2021-01-20
BR112014015042A8 (pt) 2017-07-04
AU2011351550B2 (en) 2017-02-02
CN108218650A (zh) 2018-06-29
US20130324715A1 (en) 2013-12-05
AU2011351550A1 (en) 2013-07-25
MX363538B (es) 2019-03-27
DK2793954T3 (da) 2021-01-04
PT3766522T (pt) 2022-06-14
CN103270004A (zh) 2013-08-28
EP2658831A1 (en) 2013-11-06
KR20190119673A (ko) 2019-10-22
RU2608932C2 (ru) 2017-01-26

Similar Documents

Publication Publication Date Title
KR102218263B1 (ko) 용리제 용액
US11077216B2 (en) Formulation and method of synthesis
US10023525B2 (en) Preparation of 18F-fluciclovine
EP2793954B1 (en) 18f-fluciclovine compositions in citrate buffers
Svadberg et al. Degradation of acetonitrile in eluent solutions for [18F] fluoride PET chemistry: impact on radiosynthesis of [18F] FACBC and [18F] FDG
US11534494B2 (en) Formulation and method of synthesis
US20220001034A1 (en) Novel formulation and method of synthesis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130628

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180302

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180917

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180917

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180502

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20181213

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181114

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20180917

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180502

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180302

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190114

PJ0201 Trial against decision of rejection

Patent event date: 20190114

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20181213

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20180917

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2019101000122

Request date: 20190114

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101000122; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20190114

Effective date: 20191031

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20191031

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20190114

Decision date: 20191031

Appeal identifier: 2019101000122